Therapeutic Agents

Patent metadata

Field	Value
Publication number	US-2018237784-A1
Application number	US-201615747292-A
Country	US
Kind code	A1
Filing date	Jul 27, 2016
Priority date	Jul 28, 2015
Publication date	Aug 23, 2018
Grant date	—

Abstract

The present invention relates to identification of therapeutic agents for the treatment, diagnosis, and prevention of pulmonary hypertension.

First claim

1 - 26 . (canceled)

27 . A method of treating or preventing pulmonary hypertension by: (i) modulating, antagonising or agonising ZIP12 activity, (ii) modulating ZIP12 protein levels, (iii) suppressing intracellular free zinc, or (iv) inhibiting Slc39a12 gene expression; in a subject.

28 . The method of claim 27 , wherein ZIP12 is modulated by altering the expression of gene Slc39a12.

29 . The method of claim 27 , wherein an inhibitor of ZIP12 activity or expression is administered to the subject.

30 . The method of claim 29 , wherein said inhibitor is a biological agent, a protein, a nucleic acid, an antisense oligonucleotide, siRNA, dsRNA or a pharmaceutical agent.

31 . The method of claim 29 , wherein the inhibitor is an antisense oligonucleotide, siRNA, or dsRNA which specifically binds to a portion of an mRNA encoding ZIP12.

32 . The method of claim 29 , wherein the inhibitor is an antibody, or fragment thereof, capable of binding to ZIP12.

33 . The method of claim 29 , wherein the inhibitor is an antisense oligonucleotide, siRNA, or dsRNA which specifically binds to a portion of the mRNA product of Slc39a12.

34 . The method of claim 27 , wherein the pulmonary hypertension to be prevented or treated is caused by hypoxic stress.

35 . A pharmaceutical composition comprising an inhibitor for use in the method according to claim 27 , and a pharmaceutical excipient, diluent and/or carrier.

36 . A method of diagnosing pulmonary hypertension, wherein the method comprises (i) assessing ZIP12 levels or (ii) Slc39a12 gene activity in a sample of lung tissue obtained from an individual, wherein increased ZIP12 levels or increased Slc39a12 expression levels are indicative of pulmonary hypertension.

Assignees

• Imperial Innovations Ltd

Inventors

• Oliver-Perez Eduardo
• Zhao Lan
• Wilkins Martin
• Aitman Tim

Classifications

• G01N2800/12

  Pulmonary diseases · CPC title

• G01N33/6893

  related to diseases not provided for elsewhere · CPC title

• G01N2500/10

  involving cells · CPC title

• G01N33/5008 Primary

  for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics · CPC title

• A61P9/12

  Antihypertensives · CPC title